[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100460075":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":54,"collaborators":18,"id":57,"slug":18,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":58,"sex":64,"minAge":65,"maxAge":18,"enrollmentInfo":66,"targetDuration":18,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":38,"whyStopped":18,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Medical University of Vienna","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Adsorber Group","ACTIVE_COMPARATOR","Surgery with CPB will be performed according to institutional standards, depending on indications and surgical preferences.\n\nFor the intervention group (adsorber-group), the CytoSorb adsorber will be installed on the CPB machine in a parallel circuit to the body circulation. The flow through the filter will be driven by a roller pump with 300-400 ml.min-1.",[13],"Device: CytoSorb Adsorber",{"label":15,"type":16,"description":17,"interventionNames":18},"Control","NO_INTERVENTION","The control group (no-adsorber group) will be treated similarly, but no filter circuit will be installed.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DEVICE","CytoSorb Adsorber","Polymer based adsorber system for the elimination of cytokines",[9],[26],{"name":27,"affiliation":5,"role":28},"Martin H. Bernardi, MD, PhD","PRINCIPAL_INVESTIGATOR",[30],{"name":27,"role":31,"phone":32,"phoneExt":33,"email":34},"CONTACT","0043140400","41090","martin.bernardi@meduniwien.ac.at",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Divison of Cardiac Thoracic Vascular Anaesthesia and Intensive Care, Medical University of Vienna","RECRUITING","Vienna","State of Vienna","1090","Austria",{"type":44,"coordinates":45},"Point",[46,47],16.37208,48.20849,{"lat":47,"lon":46},[50,53],{"name":51,"role":31,"phone":52,"phoneExt":18,"email":34},"Martin H Bernardi, MD","004314040041090",{"name":51,"role":28,"phone":18,"phoneExt":18,"email":18},{"type":28,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Dr. Martin Bernardi","Principal Investigator","100460075",false,"NCT05270902","Haemoadsorption During Heart Transplantation","Effect of Haemoadsorption During Cardiopulmonary Bypass on Patients After Heart Transplantation","CytoSorbHTX","Inclusion Criteria:\n\n* Adult patients undergoing heart transplantation\n\nExclusion Criteria:\n\n* Declined informed consent\n* Age \\\u003C 18 years#\n* Receiving antileukocyte drugs\n* Receiving TNF-α Blockers, immunosuppressive drugs (e.g. tocilizumab)\n* DCD\n* Ex-vivo perfusion","ALL","18 Years",{"count":67,"type":68},40,"ESTIMATED","INTERVENTIONAL",[71],"NA","To investigate whether the use of haemoadsorption (HA) on cardiopulmonary bypass during heart transplantation (HTX) has an effect on circulating cytokine levels for the first 120 hours after HTX and induces a decreased inflammatory response, increased anti-inflammatory response or immunosuppressive response. Additionally, the influence of HA on primary graft dysfunction, postoperative cerebral dysfunction, postoperative fluid accumulation, renal dysfunction, duration of mechanical ventilation, length of ICU-stay and 30-day mortality should be investigated",[74],"Heart Transplantation",[74,76],"Cytosorb","2025-05-06",{"date":79,"type":80},"2025-05-09","ACTUAL",{"date":82,"type":80},"2022-09-01",{"date":84,"type":68},"2026-06-30",{"name":5,"class":6},1]